MedTrace Logo

COVID-19 Omicron BA.5 Subvariant Dose Finding Infection Study

NCT06478420 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2026-04-24

No results posted yet for this study

Summary

A phase 1, dose-finding open label clinical infection, safety and viral detection optimization in healthy volunteers immunologically experienced against SARS-CoV-2.

Conditions

Interventions

BIOLOGICAL

Omicron BA.5 SARS-CoV-2 challenge virus

The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab taken from a patient who developed respiratory symptoms consistent with Covid-19. All manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of Colorado State University.

Sponsors & Collaborators

  • Imperial College Healthcare NHS Trust

    collaborator OTHER

  • Chelsea and Westminster Hospital, UK

    collaborator UNKNOWN

  • Royal Free London NHS Trust

    collaborator UNKNOWN

  • University of Oxford

    lead OTHER

Principal Investigators

  • Helen McShane, MD PhD · University of Oxford

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-08
Primary Completion
2028-10-31
Completion
2028-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06478420 on ClinicalTrials.gov